A Gennari, E Brain, A De Censi, O Nanni, R Wuerstlein, A Frassoldati, J Cortes, V Rossi, M Palleschi, J L Alberini, F Matteucci, A Piccardo, G Sacchetti, H Ilhan, F D'Avanzo, B Ruffilli, S Nardin, M Monti, M Puntoni, V Fontana, L Boni, N Harbeck
BACKGROUND: 18F-FES PET/CT is considered an accurate diagnostic tool to determine whole-body endocrine responsiveness. In the ET-FES trial, we evaluated 18F-FES PET/CT as a predictive tool in ER+/HER2- metastatic breast cancer (MBC). METHODS: Eligible patients underwent a 18F-FES PET/CT at baseline. Patients with SUV≥2 received single agent ET until PD; patients with SUV<2 were randomized to single agent ET (Arm A) or chemotherapy (CT) (Arm B). Primary objective was to compare the activity of first line ET versus CT in patients with 18F-FES SUV <2...
February 27, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology